HALOZYME THERAPEUTICS, INC. (HALO) Operating income 2016–2025
HALOZYME THERAPEUTICS, INC. (HALO) annual operating income history from SEC filings — each fiscal year as reported.
$469.0MFY2025 · since FY2016: -$83.2M → $469.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $469.0M | -15.0% |
| FY2024 | $551.5M | +63.4% |
| FY2023 | $337.6M | +26.2% |
| FY2022 | $267.5M | -3.0% |
| FY2021 | $275.9M | +91.3% |
| FY2020 | $144.3M | +313.4% |
| FY2019 | -$67.6M | +2.5% |
| FY2018 | -$69.3M | -185.6% |
| FY2017 | $81.0M | +197.3% |
| FY2016 | -$83.2M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More HALO financial trends
HALO RevenueHALO Net incomeHALO Net marginHALO Gross profitHALO Gross marginHALO Operating marginHALO Operating cash flowHALO Free cash flowHALO Capital expendituresHALO Return on equityHALO Stock buybacksHALO Dividends paidHALO Total assetsHALO Total liabilitiesHALO Shareholders’ equityHALO overview →